Literature DB >> 28323119

Cumulative evidence of the low reliability of frozen/thawed pig skin as a model for in vitro percutaneous permeation testing.

Amnon C Sintov1.   

Abstract

Porcine skin has frequently been used as a model in in vitro permeation studies being considered as an excellent alternative for human skin due to biochemical similarities. The use of frozen skin after thawing is particularly more convenient for these studies since it is available whenever needed. Even though several researchers have noticed that freezing and then thawing the tissue result in enhancement of drug permeation, many published articles have still described studies using frozen pig skin for bioequivalence and transdermal evaluation of drug products. The aim of this commentary article is therefore to explicitly demonstrate, according to our experience, the low-reliability of the convenient protocol of freezing pig skin for in vitro percutaneous studies. It has been shown in three separate studies using three different drugs that frozen/thawed pig skin had a higher permeability to drugs compared to that obtained by using fresh skin. The results have further demonstrated that the abnormal permeability through frozen pig skin is independent of the effect of different formulations, placing a question mark on the validity of the not freshly-used porcine skin for in vitro penetration studies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Frozen-thawed skin; Percutaneous permeation; Porcine skin; Skin model

Mesh:

Substances:

Year:  2017        PMID: 28323119     DOI: 10.1016/j.ejps.2017.03.024

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  1 in total

1.  Effect of Controlled Heat Application on Topical Diclofenac Formulations Evaluated by In Vitro Permeation Tests (IVPT) Using Porcine and Human Skin.

Authors:  Sherin Thomas; Soo Hyeon Shin; Dana C Hammell; Hazem E Hassan; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2020-02-07       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.